InsidersTradesSigma
S.M.A.I.O Stock: price and directors' dealings · France · AMF
Track the S.M.A.I.O share price and the full management transaction log of the company, a listed issuer based in France. Shares trade on FR FR, under the supervision of AMF. Operating in the Healthcare & Pharma sector, S.M.A.I.O has recorded 6 public disclosures. Market capitalisation: €46.6m. The latest transaction was filed on 24 February 2026 (Cession). Among the most active insiders: Fabrice Kilfiger. All data is openly available.
6
Insider Decl.
0
Thresholds
€72,908
3 ops.
Buy Volume
€11,672
3 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate S.M.A.I.O Strong Buy (bullish), based on 2 analysts. Average price target: €8.55.
46Σ signal
Fundamental score
Ranked 20,941 of 26,220 companies
30.7
score / 100
Value25
Quality37
FCF yld-2.8%
Earn yld-4.8%
EV/EBITDA·
ROE-35%
Gross mgn87%
Net mgn-24%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 24 February 2026
Declarations6 total
352 shares@ €7.000.018% mcap16.5% of flowActionEuronext Growth Paris2026DD1096510
199 shares@ €7.209.6% of flowActionEuronext Growth Paris2026DD1091176
500 shares@ €6.5521.9% of flowActionEuronext Growth Paris2025DD1061094
Ideal exit: 23 Jun 2026 (T+270)
1,000 shares@ €7.77552.0% of flowActionEuronext Growth Paris2025DD1052739
7,676 shares@ €3.30100.0% of flowActionEuronext Growth Paris2023DD890526
Ideal exit: 16 Dec 2023 (T+270)
13,425 shares@ €3.30100.0% of flowActionEuronext Growth Paris2023DD890227
Ideal exit: 11 Dec 2023 (T+270)
6 of 6 declarations
About S.M.A.I.O
S.M.A.I.O (SMAIO, ISIN FR0014005I80, ticker ALSMA) is a French-American medical technology company focused on complex spine surgery. Listed on Euronext Growth Paris, the company provides an integrated offering for spine surgeons that combines 3D pre-operative planning software, adaptive implants, spinal fixation systems and related services. Its business model sits at the intersection of medical devices, clinical data and surgical software, with a clear aim: to improve the precision, safety and repeatability of vertebral fusion procedures. In its official communications, SMAIO presents its offer through the i-Kontrol platform, a holistic framework covering i-PLAN for surgical planning, i-PERFORM for intra-operative execution, i-CHECK for post-operative outcome tracking and i-LEARN for physician education. The company also highlights KEOPS, its clinical database and planning software, which it describes as a global reference since its launch in 2010. Founded in 2009 and historically based in Saint-Priest near Lyon, SMAIO has progressively expanded beyond France, with a growing commercial focus on the United States, which it identifies as its highest-value and largest growth market. To support that push, the group has built a North American scientific advisory board, signed industrial partnerships and developed surgeon education programs to accelerate adoption among reference centers. In 2025, SMAIO reported a meaningful step-up in sales, driven primarily by the commercial ramp-up of its Kheiron system and by the launch of KEOPS-4ME, an open platform designed to support the wider rollout of custom K-Rods. Notable features of the company include a documented clinical database of more than 100,000 patient cases associated with KEOPS and a strategy centered on high-volume, high-complexity spine centers. SMAIO remains a small-cap healthcare company in an industrialization phase, with its investment case dependent on product adoption, international expansion and the conversion of innovation into sustainable growth and profitability.
